Call for Abstract
7th International Conference on HIV/AIDS, STDs and STIs , will be organized around the theme “Current approaches to achieving a cure for HIV infection ”
STD Conference 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in STD Conference 2019
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
HIV-related stigma and discrimination alludes to bias, pessimistic dispositions and mishandles coordinated at individuals living with HIV and AIDS. In 35% of nations with accessible information, more than half of individuals report having biased attitudes towards individuals living with HIV. Stigma and discrimination likewise make individuals defenseless against HIV. Those most in danger to HIV (key influenced populaces) keep on facing shame and segregation in view of their genuine or saw wellbeing status, race, financial status, age, sex, sexual introduction or sex personality or different grounds. Stigma and discrimination shows itself from multiple points of view. Segregation and other human rights infringement may happen in medicinal services settings, banishing individuals from getting to wellbeing administrations or appreciating quality health care.
Depending upon the illness, STDs can be spread with a sexual movement. Sexually transmitted diseases are regularly caused by infections and microbes. The accompanying is a rundown of the most widely recognized STDs, their causes. Moreover, there are different contaminations (see STDs with reference bullet mark*) that might be transmitted once in a while by sexual movement, yet these are commonly not thought to be STDs by numerous specialists. The fundamental distinction between these two classes of sexually transmitted ailments (STDs) is the thing that causes them — bacterial STDs are caused by microorganisms and viral STDs are caused by infections. Due to being caused by different microorganisms, bacterial and viral STDs move in their treatment. Bacterial STDs, for instance, gonorrhea, syphilis, and chlamydia are much of the time cured with hostile to microbial. In any case, viral STDs, (the four "H's, for example, HIV, HPV (genital warts), herpes, and hepatitis (the main STD that can be counteracted with an immunization), have no cure, yet their manifestations can be mitigated with treatment. Notwithstanding microscopic organisms and infections, STDs can likewise be caused by protozoa (trichomoniasis) and different living beings (crabs/pubic lice and scabies). These STDs can be cured with anti-microbials or topical creams/moisturizers. A standout amongst the most widely recognized side effects of a STD is no side effects. So it's imperative to go for registration. 80 percent of ladies and 40 percent of men determined to have chlamydia may not encounter indications. Sexually transmitted diseases should be analyzed effectively and completely regarded at the earliest opportunity to maintain a strategic distance from intricacies that could be not kidding and additionally changeless.
- Track 2-1Hepatitis, herpes, and human papilloma infections
- Track 2-2Trichomoniasis, syphilis, granuloma inguinale and gonorrhea
- Track 2-3Chancroid and chlamydia
- Track 2-4Reverse sequence syphilis testing: Pros and cons of syphilis screening with EIA
- Track 2-5STD prevention and statistics: The experience of a health reform state
- Track 2-6Infectious diseases in low and middle-income countries
- Track 2-7Molecular science, immunology, and the study of disease transmission of HTLV
Despite the promise of combination antiretroviral therapy and the prophylaxis of opportunistic pathogens in preventing or delaying HIV-related illnesses, some persons with HIV disease will become sick enough to require hospitalization. Nursing care of persons with HIV disease is an essential component of comprehensive patient care. The inpatient or acute care of persons with HIV disease requires intensive nursing care. In one study, Glover and colleagues concluded that patients admitted to the hospital with an AIDS diagnosis had significantly more nursing care requirements than non-AIDS patients, with the exception of those patients with AIDS admitted to critical care. Hospitalization for a person with HIV disease may represent a psychosocial transition (an experience that changes the person's view of the world), a developmental experience, a stress-inducing experience, and/or an existential crisis. Persons hospitalized with HIV disease confront profound questions related to their illness, the availability of effective treatment, their ability to pay for the care, loneliness, and the future - will they die, will they get well enough to leave the hospital, and when discharged from the hospital, will they continue to get the care and support they need. For adults with HIV disease, it is often an adjustment to increase contact with the health care system, manage the demands of treatment, and increase dependence on others, including health care providers, when they would otherwise have been self-sufficient. This change in roles and relationships almost always occurs in the course of advancing HIV disease and may be quite threatening.
- Track 4-1Systems biology in HIV, METH and cART
- Track 4-2HIV- diagnosis, retroviral transmission and prevention
- Track 4-3Mother-to-child transmission of HIV
- Track 4-4Social, cultural, economic and political issues of sexuality
- Track 4-5Opportunistic diseases in HIV
- Track 4-6Nucleoside analogues, and clinical trials in HIV/AIDS
- Track 4-7Molecular mechanisms and novel targets
The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. Here we review the current treatment options, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we consider whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the potential impact of pharmacogenomics and individualized therapy.
- Track 5-1Classes of drugs and mechanism
- Track 5-2Immunology and strategies towards HIV and retroviral infections
- Track 5-3HIV/AIDS and STDs/STIs: Vaccines research and development
- Track 5-4Nucleoside analogues and molecular mechanisms
- Track 5-5HIV: Current pharmaceutical design
Human immunodeficiency virus-infected individuals are at increased risk for CVD. Timely initiation of ART with consequent viral suppression is likely to reduce CVD events and to offset potential side effects from ART-induced metabolic changes. Reduction in smoking in HIV-infected individuals is a public health priority. Cardiovascular disease (CVD) includes a group of problems related to the heart (cardio) or to blood vessels (vascular.) CVD coronary heart disease (heart attacks), angina (chest pain from lack of blood to the heart ), cerebrovascular disease (problems with blood vessels in the brain, including stroke), high blood pressure (hypertension), peripheral artery disease (blocked blood vessels in the legs), rheumatic heart disease (a complication of a throat infection), congenital heart disease (due to a birth defect) and heart failure.
According to one estimate, bone loss may be up to three times more common overall among people with HIV than in the general population.1 Many of the traditional risk factors for osteoporosis, such as low testosterone levels, low body weight, smoking, and drinking alcohol, are also more common in the HIV-positive population and likely contribute to increased prevalence of osteoporosis and osteopenia. Bones are the foundation of our bodies; without healthy bones, we can become vulnerable to poor overall health. People with HIV are susceptible to bone loss, and to a condition called osteoporosis that may lead to fractures. In addition, as people with HIV are living longer due to effective antiretroviral therapy, bone complications may worsen as a result of aging and long-term HIV disease. Aging, antiretroviral drugs, traditional bone loss risk factors, and lifestyle all contribute to bone deterioration in the setting of HIV
The development of highly active anti-retroviral therapy (HAART) for HIV infection in the 1990s is one of modern medicine’s most dramatic success stories. Once effectively a death sentence, HIV infection can now be considered a serious, but largely manageable, chronic condition. Today, a person who begins HAART can reasonably expect to live another 30 to 50 years and often well into older age. However, many of the drugs used to treat HIV have not been around for very long. Whereas short-term side-effects are well researched and documented, longer-term side-effects are less well understood. Some HIV drugs affect the kidneys, liver, bones and heart in subtle ways. As part of your routine health monitoring, your healthcare professional will keep an eye on how well your body is working, so any problems can be identified and treated early.
It is important to know the HIV symptoms that are more common amongst women than men. Many people have no symptoms when they first become infected with HIV. Some people may have a flu-like illness (including fever, headache, tiredness and enlarged lymph nodes) within a month or two after exposure to the virus. These symptoms usually disappear within a week to a month and are often mistaken for those of another viral infection. More severe symptoms may not appear for 10 years or more. Even during the asymptomatic period, the virus is active inside a person’s body and can be passed to another person. As the immune system worsens, a variety of complications start to occur. For many people, the first signs of infection are large lymph nodes or “swollen glands” that may be enlarged for more than three months
- Track 10-1Common HIV Symptoms in Women
- Track 10-2Facts about WOMEN AND HIV/AIDS
- Track 10-3Preventing HIV in Women
- Track 10-4HIV vertical transmission (HIV in pregnant women)
Globally there are two different types of HIV epidemics. In “concentrated” epidemics, transmission occurs largely in defined vulnerable groups such as sex workers, gay men and other men who have sex with men, and people who use injection drugs. In “generalized” epidemics, transmission is sustained by sexual behavior in the general population and would persist despite effective programs for vulnerable groups. North America has a concentrated epidemic whereas sub-Saharan Africa has a generalized epidemic. HIV epidemic and assess the effectiveness of prevention efforts, the Joint United Nations Program on HIV/AIDS (UNAIDS) estimates the number of people living with HIV (prevalence) and the number of new HIV infections in one year (incidence).
- Track 11-1HIV/AIDS, STDs, & STIs epidemics across the Globe
- Track 11-2South, South-East Asia, East Asia and Pacific
- Track 11-3Latin America and the Caribbean, Eastern Europe and Central Asia
- Track 11-4Western Europe, North America, and Australasia
- Track 11-5HIV pharmacology and observational studies
- Track 11-6Gender inequalities and HIV
HIV infection represents a spectrum of disease that can begin with a brief acute retroviral syndrome that typically transitions to a multiyear chronic and clinically latent illness. Without treatment, this illness eventually progresses to a symptomatic, life-threatening immunodeficiency disease known as AIDS. In untreated patients, the time between HIV infection and the development of AIDS varies, ranging from a few months to many years with an estimated median time of approximately 11 years (123). HIV replication is present during all stages of the infection and progressively depletes CD4 lymphocytes, which are critical for maintenance of effective immune function. When the CD4 cell count falls below 200 cells/μL, patients are at high risk for life-threatening AIDS-defining opportunistic infections (e.g., Pneumocystis pneumonia, Toxoplasma gondii encephalitis, disseminated Mycobacterium avium complex disease, tuberculosis, and bacterial pneumonia). In the absence of treatment, virtually all HIV-infected persons will die of AIDS. Your health-care provider can diagnose HIV by testing blood for the presence of antibodies (disease-fighting proteins) to HIV. It may take HIV antibodies as long as six months after infection to be produced in quantities large enough to show up in standard blood tests. For that reason, make sure to talk to your health-care provider about follow-up testing.
- Track 12-1New therapeutic approaches
- Track 12-2Immunotoxins and immune-based therapies for target reservoirs of HIV-infected cells
- Track 12-3Therapeutic antibodies, gene switches, and enzymes
- Track 12-4Anti-retroviral therapies and associated complications
- Track 12-5Qualitative and quantitative, HIV-2 testing, nucleic acid-based tests (NAT)
- Track 12-6Serologic and nucleic acid amplification
- Track 12-7Window period, ELISA, western blot, rapid or point-of-care tests
- Track 12-8HIV testing and counselling
Emerging infectious diseases represent a grave threat to animal and human populations in terms of their impact on global health, agriculture and the economy. HIV Vaccines developed for emerging infections in animals can protect animal health and prevent transmission of zoonotic diseases to humans. The HIV vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. Major factors driving growth of vaccine technology market include rising prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations towards HIV/AIDS.
- Track 13-1Nanotechnology
- Track 13-2Stemcell Engineering